Category - Developments

Developments

Soligenix gets fast track designation for RiVax

The FDA granted fast track designation to Soligenix’s (NASDAQ:SNGX) RiVax for the prevention of ricin intoxication. Ricin is a lethal plant-derived toxin whose stability and high potency make it a potential biological...

February 13, 2020

Developments

Hepion advances to third dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the third dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 150 mg dosing level to be safe and...

February 12, 2020

Developments

Titan Pharma’s Probuphine listed on additional provincial drug plans in Canada

Five additional publicly-funded provincial drug plans in Canada are adding Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant to their drug benefits coverage in the fight against the opioid crisis. The provinces of...

February 12, 2020

Developments

Anixa Biosciences, Moffitt Cancer Center complete viral vector reformulation for CAR-T program

Anixa Biosciences (NASDAQ: ANIX) and the Moffitt Cancer Center, Anixa’s development partner, completed and validated the reformulation of the viral vector necessary for its CAR-T program. The purpose of the...

February 12, 2020

Developments

Bee Vectoring completes successful registration trials for commercialization in Mexico

Bee Vectoring Technologies International (TSXV:BEE; OTCQB:BEVVF) completed three official registration trials of its Clonostachys rosea CR-7 biological fungicide on commercial strawberry and tomato crops in Mexico...

February 12, 2020

Developments

PAVmed subsidiary gets breakthrough device designation for esophageal DNA test

PAVmed’s (NASDAQ:PAVM) subsidiary, Lucid Diagnostics, received FDA breakthrough device designation for its EsoGuard esophageal DNA test. The EsoGuard test, which is performed on esophageal samples collected using...

February 11, 2020

Developments

PhaseBio Pharma granted EMA PRIME designation for antiplatelet drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) received the EMA’s priority medicines, or PRIME, designation for PB2452, a drug designed to reverse the effects of antiplatelet drug, ticagrelor. Ticagrelor is administered...

February 11, 2020

Developments

OncoSec closes cash infusion and ownership stake with China Grand Pharma group

Shareholders of OncoSec Medical (NASDAQ:ONCS) approved a strategic investment and partnership with a unit of China Grand Pharmaceutical and Healthcare Holdings and its U.S. affiliate, Sirtex Medical US Holdings. Under...

February 11, 2020

Developments

Myovant reports 88% one-year response rate in Phase 3 relugolix extension study

Myovant Sciences (NASDAQ:MYOV) reported that its Phase 3 extension study of once-daily relugolix, in combination with estradiol and norethindrone acetate, achieved a one-year 88% response rate in women with uterine...

February 10, 2020

Developments

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients met its primary objective by demonstrating statistically significant improvements in HbA1c compared to placebo. The company...

February 10, 2020

Category - Developments

Subscribe